Search

What to expect

FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Mentoring peer-peer networks – a recipe for success

Isabel Peset1 & Alba Maiques-Diaz2

1 Senior Scientist, Microscopy, Medicines Discovery Catapult, Manchester, UK;
2 Postdoctoral scientist, Biomedical Epigenomics group, IDIBAPS, Barcelona, Spain; YoungEHA committee member.

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

EHA Mentorship Program eligibility

Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.

Read more

Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group

Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.

Read more